Bora Pharmaceuticals Co., LTD. (TPE:6472)

TPE:6472 Ratios and Metrics

Market cap in millions TWD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug 27, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	90,968	77,712	64,612	31,121	12,446	10,634
Market Cap Growth	3.06%	20.27%	107.61%	150.04%	17.05%	89.60%
Enterprise Value	106,429	92,091	67,752	36,584	13,828	11,299
Last Close Price	733.00	615.77	515.22	254.86	101.35	86.26
PE Ratio	19.26	19.73	21.32	22.36	16.60	18.38
Forward PE	18.94	16.07	21.03	11.57	14.97	21.75
PS Ratio	4.27	4.04	4.55	2.97	2.54	5.91
PB Ratio	6.47	5.18	5.49	6.05	3.95	4.31
P/TBV Ratio	15.72	14.33	18.95	13.07	4.18	4.32
P/FCF Ratio	23.70	171.66	14.97	17.14	11.60	372.33
P/OCF Ratio	20.03	79.23	14.01	15.48	10.07	59.81
EV/Sales Ratio	4.99	4.79	4.77	3.49	2.82	6.28
EV/EBITDA Ratio	25.85	21.72	11.82	16.87	11.42	31.90
EV/EBIT Ratio	35.05	27.23	12.91	19.03	13.22	49.98
EV/FCF Ratio	27.73	203.42	15.70	20.15	12.89	395.62
Debt / Equity Ratio	1.26	1.26	0.42	1.48	0.70	1.17
Debt / EBITDA Ratio	4.09	4.36	0.86	3.44	1.80	7.88
Debt / FCF Ratio	4.63	41.91	1.16	4.18	2.07	100.89
Asset Turnover	0.50	0.54	0.59	0.70	0.68	0.35
Inventory Turnover	3.21	3.01	3.48	5.19	3.16	1.56
Quick Ratio	1.05	1.26	0.91	0.95	0.96	0.61
Current Ratio	1.45	1.71	1.29	1.17	1.52	1.15
Return on Equity (ROE)	39.21%	30.18%	36.34%	33.80%	26.69%	28.09%
Return on Assets (ROA)	4.77%	5.98%	13.70%	7.97%	9.10%	2.72%
Return on Capital (ROIC)	6.48%	8.33%	22.25%	13.27%	12.20%	3.36%
Return on Capital Employed (ROCE)	11.00%	10.60%	31.10%	15.70%	18.90%	4.80%
Earnings Yield	4.57%	5.07%	4.69%	4.47%	6.02%	5.44%
FCF Yield	4.22%	0.58%	6.68%	5.83%	8.62%	0.27%
Dividend Yield	1.59%	1.90%	1.94%	2.01%	2.01%	1.08%
Payout Ratio	37.59%	31.30%	20.43%	17.16%	14.64%	14.39%
Buyback Yield / Dilution	-19.85%	-8.17%	-4.93%	-1.41%	-0.86%	-7.55%
Total Shareholder Return	-18.26%	-6.28%	-2.99%	0.61%	1.16%	-6.47%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.